Blinatumomab + Dexamethasone + Vincrisitne + Daunorubicin + Methotrexate + Ifosfamide + PEG-asparaginase + Erwinia-asparaginase
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Acute Lymphoblastic
Conditions
Leukemia, Acute Lymphoblastic
Trial Timeline
Nov 10, 2015 → Nov 21, 2022
NCT ID
NCT02393859About Blinatumomab + Dexamethasone + Vincrisitne + Daunorubicin + Methotrexate + Ifosfamide + PEG-asparaginase + Erwinia-asparaginase
Blinatumomab + Dexamethasone + Vincrisitne + Daunorubicin + Methotrexate + Ifosfamide + PEG-asparaginase + Erwinia-asparaginase is a phase 3 stage product being developed by Amgen for Leukemia, Acute Lymphoblastic. The current trial status is completed. This product is registered under clinical trial identifier NCT02393859. Target conditions include Leukemia, Acute Lymphoblastic.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Acute Lymphoblastic were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02393859 | Phase 3 | Completed |
Competing Products
20 competing products in Leukemia, Acute Lymphoblastic